How much funding has Evergreen Theragnostics raised?

Evergreen Theragnostics has raised $202.0M in total funding, most recently a Series A round.

Who are Evergreen Theragnostics's investors?

Evergreen Theragnostics's investors include Lantheus Holdings, Petrichor, RA Capital Management, LIFTT EuroInvest, Club degli Investitori.

When was Evergreen Theragnostics founded?

Evergreen Theragnostics was founded in 2019.

Where is Evergreen Theragnostics headquartered?

Evergreen Theragnostics is headquartered in Springfield, New Jersey, United States.

What industry is Evergreen Theragnostics in?

Evergreen Theragnostics operates in Biotech, Healthcare.

How many employees does Evergreen Theragnostics have?

Evergreen Theragnostics has 51-200 employees.

Evergreen Theragnostics

Acquired

Improving the options for cancer patients through theragnostic radiopharmaceuticals

Springfield, United States · Founded 2019 · $202.0M raised

Biotech

Healthcare

Headquarters: Springfield, New Jersey
Employees: 51–200
Founded: 2019
Business Model: B2B
Website: evergreentgn.com

Total Funding: $202.0M
Last Round: $19.0M Series AJun 2026
Rounds: 7
Acquired by: Lantheus HoldingsJan 2025

About

Evergreen Theragnostics is a radiopharmaceutical CDMO specializing in theragnostic solutions for cancer treatment. The company develops and manufactures targeted radiopharmaceuticals including Gallium-68 DOTATOC diagnostic kits and targeted alpha therapy agents. Acquired by Lantheus in 2025.

Summary

Evergreen Theragnostics is a Biotech company based in Springfield, United States, founded in 2019. It has raised $202.0M in total across 7 rounds, most recently a $19.0M Series A round in Jun 2026. Investors include Lantheus Holdings, Petrichor and RA Capital Management.